Sanctuary Advisors LLC Has $109,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Sanctuary Advisors LLC cut its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 20.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,184 shares of the company’s stock after selling 7,656 shares during the quarter. Sanctuary Advisors LLC’s holdings in ImmunityBio were worth $109,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of IBRX. Captrust Financial Advisors acquired a new stake in shares of ImmunityBio in the third quarter valued at about $41,000. Algert Global LLC bought a new position in ImmunityBio in the 2nd quarter worth approximately $86,000. Virtu Financial LLC acquired a new position in shares of ImmunityBio during the third quarter worth approximately $51,000. Dimensional Fund Advisors LP bought a new stake in shares of ImmunityBio in the second quarter valued at approximately $105,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of ImmunityBio in the second quarter worth $118,000. Institutional investors own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IBRX shares. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Friday, December 20th.

ImmunityBio Trading Down 3.6 %

IBRX opened at $2.68 on Tuesday. The stock’s 50 day simple moving average is $4.40 and its 200-day simple moving average is $4.60. The stock has a market cap of $1.87 billion, a PE ratio of -2.91 and a beta of 0.86. ImmunityBio, Inc. has a 1 year low of $2.50 and a 1 year high of $10.53.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.